[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-407598-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-407598-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","coronary-artery-bypass-grafting-in-patients-with-hematological-neoplasms","Coronary artery bypass grafting in patients with hematological neoplasms","","Study examines outcomes and clinical factors in patients with hematological neoplasms undergoing coronary artery bypass grafting. The text reports baseline characteristics, including platelet-related measures and comorbid conditions, and presents group comparisons using endpoints such as overall and event-related outcomes. Results summarize distributions of platelet counts and classifications, along with survival and complication profiles, highlighting statistically assessed differences between subgroups. Limitations and interpretation focus on how hematologic disease and platelet status may influence postoperative risk and prognosis.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/coronary-artery-bypass-grafting-in-patients-with-hematological-neoplasms/407598/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/coronary-artery-bypass-grafting-in-patients-with-hematological-neoplasms/407598.png","ImageObject",300,407,{"name":42,"@type":43},"Angel","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-02","2026-09-28",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What does the study focus on regarding coronary artery bypass grafting?","Question",{"text":63,"@type":64},"It focuses on how patients with hematological neoplasms fare after coronary artery bypass grafting, including reported outcomes and associated clinical factors.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How are platelet-related measures used in the analysis?",{"text":68,"@type":64},"The text describes platelet count distributions and categorization, then relates these measures to outcomes through subgroup comparisons and statistical testing.",{"name":70,"@type":61,"acceptedAnswer":71},"What types of outcomes are summarized in the results?",{"text":72,"@type":64},"The results summarize survival and event-related outcomes, along with complication or risk profiles, and present percentages for different patient groups.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},407598,1790695531,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":124,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},687207412472,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","TYPE O􀀉􀀅􀀝􀀅􀀂􀀈􀀋 R􀀍􀀓􀀍􀀈􀀉􀀖h PUB􀀕I􀀜􀀝ED 17 􀀑􀀍􀀖􀀍􀀗b􀀍􀀉 2025 DOI 10.3389/􀀘􀀖􀀛􀀗 .2025.1697389  \n􀀁􀀂􀀃􀀄􀀁􀀂 􀀆􀀇  \n􀀁􀀂􀀃􀀄􀀂􀀅􀀄 􀀇􀀈􀀉􀀅􀀈 􀀊􀀈􀀋􀀈􀀌􀀄􀀉􀀍􀀎  \n􀀏􀀍􀀂􀀉􀀐 􀀑􀀒􀀂􀀈􀀂􀀃 􀀏􀀄􀀓􀀔􀀅􀀃􀀈􀀋􀀎 􀀕􀀉􀀍􀀍􀀖􀀍  \n􀀈􀀁􀀉􀀃􀀁􀀊􀀁􀀂 􀀆􀀇  \n􀀁􀀗􀀉 􀀁􀀉􀀈􀀘􀀈􀀃􀀎  \n􀀙􀀈􀀂􀀃􀀈 􀀚􀀂􀀅􀀛􀀍􀀉􀀓􀀅􀀃􀀐􀀎 􀀜􀀝􀀐􀀔􀀃􀀑􀀒􀀞􀀐 􀀁􀀉􀀗􀀈􀀂 􀀏􀀈􀀂􀀈􀀘􀀐􀀎  \n􀀚􀀂􀀅􀀛􀀍􀀉􀀓􀀅􀀃􀀐 􀀄􀀘 􀀂􀀞􀀄􀀂􀀍􀀓􀀅􀀈􀀎 􀀂􀀞􀀄􀀂􀀍􀀓􀀅􀀈 R􀀈􀀘􀀘􀀈􀀍􀀋􀀍 B􀀄􀀂􀀅􀀘􀀈z􀀅􀀎  \n􀀁􀀂􀀃h􀀍􀀈 􀀏􀀄􀀓􀀔􀀅􀀃􀀈􀀋􀀎 􀀃􀀈􀀋􀀐  \n*􀀋􀀌􀀈􀀈􀀁􀀍􀀎􀀌􀀏􀀂􀀁􀀏􀀋􀀁  \nY􀀅 Sh􀀅  \n 􀀓h􀀅􀀐􀀅􀀞􀀄􀀖􀀃􀀄􀀉@163 .􀀖􀀄􀀗  \n†􀀙h􀀍􀀓􀀍 􀀈􀀒􀀃h􀀄􀀉􀀓 h􀀈􀀛􀀍 􀀖􀀄􀀂􀀃􀀉􀀅b􀀒􀀃􀀍􀀞 􀀍q􀀒􀀈􀀋􀀋􀀐 􀀃􀀄􀀃h􀀅􀀓 w􀀄􀀉k  \n􀀈􀀁􀀋􀀁􀀃􀀉􀀁􀀂 02 S􀀍􀀔􀀃􀀍􀀗b􀀍􀀉 2025  \n􀀈􀀁􀀉􀀃􀀍􀀁􀀂 25 N􀀄􀀛􀀍􀀗b􀀍􀀉 2025  \n􀀐􀀋􀀋􀀁􀀎􀀄􀀁􀀂 02 􀀑􀀍􀀖􀀍􀀗b􀀍􀀉 2025  \n􀀎􀀑􀀆􀀒􀀃􀀍􀀓􀀁􀀂 17 􀀑􀀍􀀖􀀍􀀗b􀀍􀀉 2025  \n􀀋􀀃􀀄􀀐􀀄􀀃􀀌􀀏  \nZh􀀈􀀂􀀝 L􀀎 Zh􀀈􀀂􀀝 S􀀎 J􀀅􀀈􀀂􀀝 􀀏􀀎 L􀀅􀀒 J􀀎 􀀕􀀈􀀄 Q􀀎 L􀀅􀀈􀀂 B􀀎 L􀀅􀀒 Z 􀀈􀀂􀀞 Sh􀀅 Y (2025) 􀀊􀀄􀀉􀀄􀀂􀀈􀀉􀀐 􀀈􀀉􀀃􀀍􀀉􀀐 b􀀐􀀔􀀈􀀓􀀓 􀀝􀀉􀀈􀀘􀀃􀀅􀀂􀀝 􀀅􀀂 􀀔􀀈􀀃􀀅􀀍􀀂􀀃􀀓 w􀀅􀀃h h􀀍􀀗􀀈􀀃􀀄􀀋􀀄􀀝􀀅􀀖􀀈􀀋􀀂􀀍􀀄􀀔􀀋􀀈􀀓􀀗􀀓 .  \nF􀀉􀀄􀀂􀀃 . 􀀊􀀈􀀉􀀞􀀅􀀄􀀛􀀈􀀓􀀖 . 􀀇􀀍􀀞 . 12:1697389 .􀀞􀀄􀀅: 10.3389/􀀘􀀖􀀛􀀗 .2025.1697389  \n􀀋􀀌􀀎􀀇􀀈􀀃􀀔􀀓􀀄  \n© 2025 Zh􀀈􀀂􀀝􀀎 Zh􀀈􀀂􀀝􀀎 J􀀅􀀈􀀂􀀝􀀎 L􀀅􀀒􀀎 􀀕􀀈􀀄􀀎 L􀀅􀀈􀀂􀀎 L􀀅􀀒 􀀈􀀂􀀞 Sh􀀅 . 􀀙h􀀅􀀓 􀀅􀀓 􀀈􀀂 􀀄􀀔􀀍􀀂-􀀈􀀖􀀖􀀍􀀓􀀓 􀀈􀀉􀀃􀀅􀀖􀀋􀀍􀀞􀀅􀀓􀀃􀀉􀀅b􀀒􀀃􀀍􀀞 􀀒􀀂􀀞􀀍􀀉 􀀃h􀀍 􀀃􀀍􀀉􀀗􀀓 􀀄􀀘 􀀃h􀀍 􀀊􀀉􀀍􀀈􀀃􀀅􀀛􀀍􀀊􀀄􀀗􀀗􀀄􀀂􀀓 􀀁􀀃􀀃􀀉􀀅b􀀒􀀃􀀅􀀄􀀂 L􀀅􀀖􀀍􀀂􀀓􀀍 (􀀊􀀊 BY) . 􀀙h􀀍􀀒􀀓􀀍􀀎 􀀞􀀅􀀓􀀃􀀉􀀅b􀀒􀀃􀀅􀀄􀀂 􀀄􀀉 􀀉􀀍􀀔􀀉􀀄􀀞􀀒􀀖􀀃􀀅􀀄􀀂 􀀅􀀂 􀀄􀀃h􀀍􀀉􀀘􀀄􀀉􀀒􀀗􀀓 􀀅􀀓 􀀔􀀍􀀉􀀗􀀅􀀃􀀃􀀍􀀞􀀎 􀀔􀀉􀀄􀀛􀀅􀀞􀀍􀀞 􀀃h􀀍 􀀄􀀉􀀅􀀝􀀅􀀂􀀈􀀋􀀈􀀒􀀃h􀀄􀀉(􀀓) 􀀈􀀂􀀞 􀀃h􀀍 􀀖􀀄􀀔􀀐􀀉􀀅􀀝h􀀃 􀀄w􀀂􀀍􀀉(􀀓) 􀀈􀀉􀀍􀀖􀀉􀀍􀀞􀀅􀀃􀀍􀀞 􀀈􀀂􀀞 􀀃h􀀈􀀃 􀀃h􀀍 􀀄􀀉􀀅􀀝􀀅􀀂􀀈􀀋 􀀔􀀒b􀀋􀀅􀀖􀀈􀀃􀀅􀀄􀀂 􀀅􀀂􀀃h􀀅􀀓 j􀀄􀀒􀀉􀀂􀀈􀀋 􀀅􀀓 􀀖􀀅􀀃􀀍􀀞􀀎 􀀅􀀂 􀀈􀀖􀀖􀀄􀀉􀀞􀀈􀀂􀀖􀀍 w􀀅􀀃h 􀀈􀀖􀀖􀀍􀀔􀀃􀀍􀀞 􀀈􀀖􀀈􀀞􀀍􀀗􀀅􀀖 􀀔􀀉􀀈􀀖􀀃􀀅􀀖􀀍 . N􀀄 􀀒􀀓􀀍􀀎􀀞􀀅􀀓􀀃􀀉􀀅b􀀒􀀃􀀅􀀄􀀂 􀀄􀀉 􀀉􀀍􀀔􀀉􀀄􀀞􀀒􀀖􀀃􀀅􀀄􀀂 􀀅􀀓 􀀔􀀍􀀉􀀗􀀅􀀃􀀃􀀍􀀞 wh􀀅􀀖h 􀀞􀀄􀀍􀀓 􀀂􀀄􀀃 􀀖􀀄􀀗􀀔􀀋􀀐 w􀀅􀀃h 􀀃h􀀍􀀓􀀍 􀀃􀀍􀀉􀀗􀀓 .  \n􀀁􀀂􀀃􀀂􀀄􀀅􀀃􀀆 􀀅􀀃􀀈􀀉􀀃􀀆 􀀊􀀆􀀋􀀅􀀌􀀌 􀀍􀀃􀀅􀀎􀀈􀀏􀀄􀀍􀀏􀀄 􀀋􀀅􀀈􀀏􀀉􀀄􀀈􀀌 􀀐􀀏􀀈􀀑 􀀑􀀉􀀒􀀅􀀈􀀂􀀓􀀂􀀍􀀏􀀔􀀅􀀓􀀄􀀉􀀂􀀋􀀓􀀅􀀌􀀒􀀌  \n􀀕􀀏􀀖􀀗􀀉 􀀘􀀑􀀅􀀄􀀍 􀀙􀀚􀀛 􀀜􀀏􀀒􀀉􀀄􀀍 􀀘􀀑􀀅􀀄􀀍 􀀙􀀚􀀛 􀀝􀀅􀀂 􀀞􀀏􀀅􀀄􀀍 􀀛 􀀞􀀏􀀅􀀄 􀀕􀀏􀀗 3􀀛 Q􀀏􀀄􀀍 G􀀅􀀂􀀙􀀛 B􀀂 􀀕􀀏􀀅􀀄 􀀙􀀛 􀀘􀀉􀀆􀀉 􀀕􀀏􀀗 􀀙 􀀅􀀄d Y􀀏 􀀜􀀑􀀏 􀀙*  \n1 􀀑􀀍􀀔􀀈􀀉􀀃􀀗􀀍􀀂􀀃 􀀄􀀘 􀀊􀀈􀀉􀀞􀀅􀀈􀀖 S􀀒􀀉􀀝􀀍􀀉􀀐􀀎 P􀀍k􀀅􀀂􀀝 􀀚􀀂􀀅􀀛􀀍􀀉􀀓􀀅􀀃􀀐 P􀀍􀀄􀀔􀀋􀀍’􀀓 􀀏􀀄􀀓􀀔􀀅􀀃􀀈􀀋􀀎 B􀀍􀀅j􀀅􀀂􀀝􀀎 􀀊h􀀅􀀂􀀈􀀎 2 􀀑􀀍􀀔􀀈􀀉􀀃􀀗􀀍􀀂􀀃 􀀄􀀘􀀏􀀍􀀗􀀈􀀃􀀄􀀋􀀄􀀝􀀐􀀎 P􀀍k􀀅􀀂􀀝 􀀚􀀂􀀅􀀛􀀍􀀉􀀓􀀅􀀃􀀐 P􀀍􀀄􀀔􀀋􀀍’􀀓 􀀏􀀄􀀓􀀔􀀅􀀃􀀈􀀋􀀎 B􀀍􀀅j􀀅􀀂􀀝􀀎 􀀊h􀀅􀀂􀀈􀀎 3􀀑􀀍􀀔􀀈􀀉􀀃􀀗􀀍􀀂􀀃 􀀄􀀘 􀀊􀀈􀀉􀀞􀀅􀀄􀀋􀀄􀀝􀀐􀀎 P􀀍k􀀅􀀂􀀝􀀚􀀂􀀅􀀛􀀍􀀉􀀓􀀅􀀃􀀐 P􀀍􀀄􀀔􀀋􀀍’􀀓 􀀏􀀄􀀓􀀔􀀅􀀃􀀈􀀋􀀎 B􀀍􀀅j􀀅􀀂􀀝􀀎 􀀊h􀀅􀀂􀀈  \n􀀆􀀕􀀖􀀗􀀘􀀙􀀚􀀛􀀜􀀝􀀞 􀀊􀀄􀀉􀀄􀀂􀀈􀀉􀀐 􀀈􀀉􀀃􀀍􀀉􀀐 b􀀐􀀔􀀈􀀓􀀓 􀀝􀀉􀀈􀀘􀀃􀀅􀀂􀀝 (􀀊􀀁B􀀕) 􀀅􀀂 􀀔􀀈􀀃􀀅􀀍􀀂􀀃􀀓 w􀀅􀀃h 􀀖􀀄􀀂􀀖􀀒􀀉􀀉􀀍􀀂􀀃􀀖􀀄􀀉􀀄􀀂􀀈􀀉􀀐 􀀈􀀉􀀃􀀍􀀉􀀐 􀀞􀀅􀀓􀀍􀀈􀀓􀀍 (􀀊􀀁􀀑) 􀀈􀀂􀀞 h􀀍􀀗􀀈􀀃􀀄􀀋􀀄􀀝􀀅􀀖􀀈􀀋 􀀂􀀍􀀄􀀔􀀋􀀈􀀓􀀗􀀓 􀀔􀀉􀀍􀀓􀀍􀀂􀀃􀀓 􀀒􀀂􀀅q􀀒􀀍􀀖h􀀈􀀋􀀋􀀍􀀂􀀝􀀍􀀓 􀀞􀀒􀀍 􀀃􀀄 􀀅􀀗􀀗􀀒􀀂􀀄􀀓􀀒􀀔􀀔􀀉􀀍􀀓􀀓􀀅􀀄􀀂􀀎 h􀀍􀀗􀀈􀀃􀀄􀀋􀀄􀀝􀀅􀀖 􀀞􀀐􀀓􀀘􀀒􀀂􀀖􀀃􀀅􀀄􀀂􀀎 􀀈􀀂􀀞􀀖􀀄􀀈􀀝􀀒􀀋􀀄􀀔􀀈􀀃h􀀐 . 􀀙h􀀅􀀓 􀀓􀀃􀀒􀀞􀀐 􀀈􀀅􀀗􀀍􀀞 􀀃􀀄 􀀈􀀓􀀓􀀍􀀓􀀓 􀀃h􀀍 􀀓􀀈􀀘􀀍􀀃􀀐 􀀈􀀂􀀞 􀀘􀀍􀀈􀀓􀀅b􀀅􀀋􀀅􀀃􀀐 􀀄􀀘 􀀊􀀁B􀀕 􀀅􀀂􀀃h􀀅􀀓 􀀔􀀄􀀔􀀒􀀋􀀈􀀃􀀅􀀄􀀂 􀀈􀀂􀀞 􀀃􀀄 􀀍􀀛􀀈􀀋􀀒􀀈􀀃􀀍 􀀘􀀈􀀖􀀃􀀄􀀉􀀓 􀀅􀀂fl􀀒􀀍􀀂􀀖􀀅􀀂􀀝 􀀔􀀉􀀄􀀝􀀂􀀄􀀓􀀅􀀓 .  \neth􀀚􀀝s􀀞 􀀙h􀀅􀀓 􀀉􀀍􀀃􀀉􀀄􀀓􀀔􀀍􀀖􀀃􀀅􀀛􀀍 􀀓􀀃􀀒􀀞􀀐 􀀅􀀂􀀖􀀋􀀒􀀞􀀍􀀞 41 􀀔􀀈􀀃􀀅􀀍􀀂􀀃􀀓 w􀀅􀀃h 􀀊􀀁􀀑 􀀈􀀂􀀞 h􀀍􀀗􀀈􀀃􀀄􀀋􀀄􀀝􀀅􀀖􀀈􀀋 􀀂􀀍􀀄􀀔􀀋􀀈􀀓􀀗􀀓 wh􀀄 􀀒􀀂􀀞􀀍􀀉w􀀍􀀂􀀃 􀀊􀀁B􀀕 b􀀍􀀃w􀀍􀀍􀀂 2018 􀀈􀀂􀀞 2023 .􀀏􀀍􀀗􀀈􀀃􀀄􀀋􀀄􀀝􀀅􀀖􀀈􀀋 􀀂􀀍􀀄􀀔􀀋􀀈􀀓􀀗􀀓 w􀀍􀀉􀀍 􀀖􀀋􀀈􀀓􀀓􀀅􀀌􀀍􀀞 􀀅􀀂􀀃􀀄 􀀓􀀍􀀛􀀍􀀂 􀀖􀀈􀀃􀀍􀀝􀀄􀀉􀀅􀀍􀀓􀀎 􀀈􀀂􀀞 􀀔􀀈􀀃􀀅􀀍􀀂􀀃􀀓 w􀀍􀀉􀀍 􀀓􀀃􀀉􀀈􀀃􀀅􀀌􀀍􀀞 b􀀐 h􀀍􀀗􀀈􀀃􀀄􀀋􀀄􀀝􀀅􀀖􀀈􀀋 􀀞􀀅􀀓􀀍􀀈􀀓􀀍 􀀓􀀃􀀈􀀃􀀒􀀓: 􀀓􀀃􀀈b􀀋􀀍􀀎 􀀞􀀅􀀓􀀍􀀈􀀓􀀍-􀀘􀀉􀀍􀀍􀀎 􀀄􀀉􀀔􀀉􀀄􀀝􀀉􀀍􀀓􀀓􀀅􀀛􀀍 . K􀀍􀀐 􀀔􀀍􀀉􀀅􀀄􀀔􀀍􀀉􀀈􀀃􀀅􀀛􀀍 􀀄􀀒􀀃􀀖􀀄􀀗􀀍􀀓􀀎 􀀝􀀉􀀈􀀘􀀃 􀀔􀀈􀀃􀀍􀀂􀀖􀀐􀀎 􀀈􀀂􀀞 􀀓􀀒􀀉􀀛􀀅􀀛􀀈􀀋 􀀞􀀈􀀃􀀈 w􀀍􀀉􀀍 􀀈􀀂􀀈􀀋􀀐z􀀍􀀞 . 􀀊􀀄x 􀀉􀀍􀀝􀀉􀀍􀀓􀀓􀀅􀀄􀀂 􀀗􀀄􀀞􀀍􀀋􀀓 􀀅􀀞􀀍􀀂􀀃􀀅􀀌􀀍􀀞 􀀅􀀂􀀞􀀍􀀔􀀍􀀂􀀞􀀍􀀂􀀃 􀀔􀀉􀀍􀀞􀀅􀀖􀀃􀀄􀀉􀀓􀀄􀀘 􀀔􀀉􀀄􀀝􀀂􀀄􀀓􀀅􀀓 .  \n􀀈es􀀛lts􀀞 O􀀘 􀀃h􀀍 41 􀀔􀀈􀀃􀀅􀀍􀀂􀀃􀀓􀀎 28 (68 .3%) w􀀍􀀉􀀍 􀀓􀀃􀀈b􀀋􀀍􀀎 10 (24 .4%) w􀀍􀀉􀀍 􀀞􀀅􀀓􀀍􀀈􀀓􀀍 -􀀘􀀉􀀍􀀍􀀎 􀀈􀀂􀀞 3 (7 .3%) w􀀍􀀉􀀍 􀀔􀀉􀀄􀀝􀀉􀀍􀀓􀀓􀀅􀀛􀀍 . 􀀙h􀀍 􀀗􀀍􀀞􀀅􀀈􀀂 􀀔􀀉􀀍􀀄􀀔􀀍􀀉􀀈􀀃􀀅􀀛􀀍 􀀔􀀋􀀈􀀃􀀍􀀋􀀍􀀃 􀀖􀀄􀀒􀀂􀀃 w􀀈􀀓 143 × 109/L􀀎 w􀀅􀀃h 8 􀀔􀀈􀀃􀀅􀀍􀀂􀀃􀀓 􀀔􀀉􀀍􀀓􀀍􀀂􀀃􀀅􀀂􀀝 􀀖􀀄􀀒􀀂􀀃􀀓 \u003C50 × 109/L 􀀉􀀍q􀀒􀀅􀀉􀀅􀀂􀀝􀀔􀀉􀀍􀀄􀀔􀀍􀀉􀀈􀀃􀀅􀀛􀀍 􀀔􀀋􀀈􀀃􀀍􀀋􀀍􀀃 􀀃􀀉􀀈􀀂􀀓􀀘􀀒􀀓􀀅􀀄􀀂􀀓 . P􀀄􀀓􀀃􀀄􀀔􀀍􀀉􀀈􀀃􀀅􀀛􀀍 􀀃􀀉􀀈􀀂􀀓􀀘􀀒􀀓􀀅􀀄􀀂 􀀉􀀈􀀃􀀍􀀓 􀀘􀀄􀀉 􀀔􀀈􀀖k􀀍􀀞􀀉􀀍􀀞 b􀀋􀀄􀀄􀀞 􀀖􀀍􀀋􀀋􀀓 (PR B􀀊􀀓)􀀎 􀀘􀀉􀀍􀀓h 􀀘􀀉􀀄z􀀍􀀂 􀀔􀀋􀀈􀀓􀀗􀀈 (FF P) 􀀈􀀂􀀞 􀀔􀀋􀀈􀀃􀀍􀀋􀀍􀀃􀀓 w􀀍􀀉􀀍 51.2%􀀎 39. 0%􀀎 􀀈􀀂􀀞 12 . 2%􀀎 􀀉􀀍􀀓􀀔􀀍􀀖􀀃􀀅􀀛􀀍􀀋􀀐 . 􀀙h􀀍 􀀗􀀍􀀞􀀅􀀈􀀂 􀀄􀀔􀀍􀀉􀀈􀀃􀀅􀀄􀀂 􀀃􀀅􀀗􀀍 w􀀈􀀓 210 􀀗􀀅􀀂􀀎 w􀀅􀀃h 87. 8% 􀀒􀀂􀀞􀀍􀀉􀀝􀀄􀀅􀀂􀀝 􀀄􀀘􀀘-􀀔􀀒􀀗􀀔 􀀊􀀁B􀀕 . 􀀕􀀉􀀈􀀘􀀃 􀀔􀀈􀀃􀀍􀀂􀀖􀀐 􀀈􀀃 􀀞􀀅􀀓􀀖h􀀈􀀉􀀝􀀍 w􀀈􀀓 92 .3% .􀀇􀀈j􀀄􀀉 􀀅􀀂􀀘􀀍􀀖􀀃􀀅􀀄􀀂􀀓 􀀄􀀖􀀖􀀒􀀉􀀉􀀍􀀞 􀀅􀀂 4.9% 􀀄􀀘 􀀔􀀈􀀃􀀅􀀍􀀂􀀃􀀓􀀎 􀀈􀀂􀀞 9 (22%) 􀀞􀀍􀀈􀀃h􀀓 w􀀍􀀉􀀍􀀉􀀍􀀖􀀄􀀉􀀞􀀍􀀞 􀀞􀀒􀀉􀀅􀀂􀀝 􀀘􀀄􀀋􀀋􀀄w-􀀒􀀔􀀎 8 􀀞􀀒􀀍 􀀃􀀄 h􀀍􀀗􀀈􀀃􀀄􀀋􀀄􀀝􀀅􀀖􀀈􀀋 􀀔􀀉􀀄􀀝􀀉􀀍􀀓􀀓􀀅􀀄􀀂 􀀈􀀂􀀞 1 􀀞􀀒􀀍 􀀃􀀄􀀗􀀐􀀄􀀖􀀈􀀉􀀞􀀅􀀈􀀋 􀀅􀀂􀀘􀀈􀀉􀀖􀀃􀀅􀀄􀀂 . 􀀊􀀄x 􀀉􀀍􀀝􀀉􀀍􀀓􀀓􀀅􀀄􀀂 􀀅􀀞􀀍􀀂􀀃􀀅􀀌􀀍􀀞 􀀔􀀉􀀍􀀄􀀔􀀍􀀉􀀈􀀃􀀅􀀛􀀍 b􀀋􀀄􀀄􀀞 􀀖􀀍􀀋􀀋 􀀋􀀍􀀛􀀍􀀋􀀓􀀈􀀓 􀀅􀀂􀀞􀀍􀀔􀀍􀀂􀀞􀀍􀀂􀀃 􀀔􀀉􀀍􀀞􀀅􀀖􀀃􀀄􀀉􀀓 􀀄􀀘 􀀓􀀒􀀉􀀛􀀅􀀛􀀈􀀋 ( 􀀁 \u003C 0 . 05)􀀎 wh􀀅􀀋􀀍 􀀊􀀁B􀀕-􀀉􀀍􀀋􀀈􀀃􀀍􀀞 􀀘􀀈􀀖􀀃􀀄􀀉􀀓􀀓h􀀄w􀀍􀀞 􀀂􀀄 􀀓􀀅􀀝􀀂􀀅􀀌􀀖􀀈􀀂􀀃 􀀈􀀓􀀓􀀄􀀖􀀅􀀈􀀃􀀅􀀄􀀂 ( 􀀁 > 0 . 05) .  \n􀀋􀀚􀀜􀀖l􀀛si􀀚􀀜s􀀞 􀀊􀀁B􀀕 􀀖􀀈􀀂 b􀀍 􀀔􀀍􀀉􀀘􀀄􀀉􀀗􀀍􀀞 􀀓􀀈􀀘􀀍􀀋􀀐 􀀅􀀂 􀀗􀀄􀀓􀀃 􀀔􀀈􀀃􀀅􀀍􀀂􀀃􀀓 w􀀅􀀃h 􀀓􀀃􀀈b􀀋􀀍 h􀀍􀀗􀀈􀀃􀀄􀀋􀀄􀀝􀀅􀀖􀀈􀀋 􀀂􀀍􀀄􀀔􀀋􀀈􀀓􀀗􀀓􀀎 w􀀅􀀃h 􀀂􀀄 􀀔􀀍􀀉􀀅􀀄􀀔􀀍􀀉􀀈􀀃􀀅􀀛􀀍 􀀗􀀄􀀉􀀃􀀈􀀋􀀅􀀃􀀐􀀎 􀀔􀀉􀀄􀀛􀀅􀀞􀀅􀀂􀀝 􀀈􀀂􀀄􀀔􀀔􀀄􀀉􀀃􀀒􀀂􀀅􀀃􀀐 􀀘􀀄􀀉 􀀘􀀒􀀉􀀃h􀀍􀀉 h􀀍􀀗􀀈􀀃􀀄􀀋􀀄􀀝􀀅􀀖􀀈􀀋 􀀃􀀉􀀍􀀈􀀃􀀗􀀍􀀂􀀃􀀓 . P􀀉􀀍􀀄􀀔􀀍􀀉􀀈􀀃􀀅􀀛􀀍 b􀀋􀀄􀀄􀀞 􀀖􀀍􀀋􀀋􀀋􀀍􀀛􀀍􀀋􀀓 􀀓􀀅􀀝􀀂􀀅􀀌􀀖􀀈􀀂􀀃􀀋􀀐 􀀅􀀂fl􀀒􀀍􀀂􀀖􀀍 􀀔􀀉􀀄􀀝􀀂􀀄􀀓􀀅􀀓􀀎 􀀒􀀂􀀞􀀍􀀉􀀓􀀖􀀄􀀉􀀅􀀂􀀝 􀀃h􀀍 􀀅􀀗􀀔􀀄􀀉􀀃􀀈􀀂􀀖􀀍 􀀄􀀘􀀗􀀒􀀋􀀃􀀅􀀞􀀅􀀓􀀖􀀅􀀔􀀋􀀅􀀂􀀈􀀉􀀐 􀀗􀀈􀀂􀀈􀀝􀀍􀀗􀀍􀀂􀀃 . L􀀈􀀉􀀝􀀍􀀉 􀀓􀀃􀀒􀀞􀀅􀀍􀀓 􀀈􀀉􀀍 􀀂􀀍􀀍􀀞􀀍􀀞 􀀃􀀄 􀀛􀀈􀀋􀀅􀀞􀀈􀀃􀀍 􀀃h􀀍􀀓􀀍􀀌􀀂􀀞􀀅􀀂􀀝􀀓 􀀈􀀂􀀞 􀀉􀀍􀀌􀀂􀀍 􀀃􀀉􀀍􀀈􀀃􀀗􀀍􀀂􀀃 􀀓􀀃􀀉􀀈􀀃􀀍􀀝􀀅􀀍􀀓 .  \nK􀀁􀀇􀀊􀀌􀀈􀀂􀀍  \n􀀋􀀐􀀆􀀔, hem􀀕t􀀚l􀀚􀀘i􀀖􀀕l 􀀜e􀀚pl􀀕sms, m􀀛lti􀀝is􀀖ipli􀀜􀀕􀀙y m􀀕􀀜􀀕􀀘eme􀀜t, 􀀖􀀚􀀙􀀚􀀜􀀕􀀙y 􀀕􀀙te􀀙y 􀀝ise􀀕se, p􀀙e􀀚pe􀀙􀀕tive bl􀀚􀀚􀀝 􀀖ell level  \nF􀀃􀀂􀀄􀀈􀀏􀀉􀀃􀀌 􀀏􀀄 􀀁􀀅􀀃d􀀏􀀂v􀀅􀀌􀀔􀀗􀀓􀀅􀀃 M􀀉d􀀏􀀔􀀏􀀄􀀉 0􀀙 􀀎􀀃􀀂􀀄􀀈􀀏􀀉􀀃􀀌􀀏􀀄 .􀀂􀀃􀀍  \nI􀀄􀀈􀀃􀀂d􀀗􀀔􀀈􀀏􀀂􀀄  \n􀀁􀀂􀀃􀀂􀀄","cbCairgWKcfwwZe0","https://ap.wps.com/l/cbCairgWKcfwwZe0","pdf",1077614,"English","# Overview\n## Study population and baseline measures\n## Outcome results and subgroup comparisons\n## Clinical interpretation and conclusions","[{\"question\":\"What does the study focus on regarding coronary artery bypass grafting?\",\"answer\":\"It focuses on how patients with hematological neoplasms fare after coronary artery bypass grafting, including reported outcomes and associated clinical factors.\"},{\"question\":\"How are platelet-related measures used in the analysis?\",\"answer\":\"The text describes platelet count distributions and categorization, then relates these measures to outcomes through subgroup comparisons and statistical testing.\"},{\"question\":\"What types of outcomes are summarized in the results?\",\"answer\":\"The results summarize survival and event-related outcomes, along with complication or risk profiles, and present percentages for different patient groups.\"}]","Coronary artery bypass grafting in patients with hematological neoplasms | PDF",1790574976,25]